Patricia A. Arndt
Research Subjects
Patricia A. Arndt has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
George Garratty
From the American Red Cross Blood Services, Southern California Region, Pomona, California
7 shared publicationsG. Garratty
American Red Cross Blood Services, Southern California Region, Pomona, California
5 shared publicationsRegina M. Leger
From the American Red Cross Blood Services, Southern California Region, Pomona, California
2 shared publicationsA. M. Wilkes
Bristol Institute for Transfusion Sciences, Bristol, UK, and
1 shared publicationAkhil Baranwal
From the American Red Cross Blood Services, Southern California Region, Los Angeles, California; and the Robert Wood Johnson University Hospital, New Brunswick, New Jersey
1 shared publicationBelinda M. Kumpel
Bristol Institute for Transfusion Sciences, International Blood Group Reference Laboratory, Bristol, UK
1 shared publication
Latest Publications
- 31 August 2011
- Published by Wiley in Transfusion
- Vol. 52 (3) , 602-612
Serologic characteristics of ceftriaxone antibodies in 25 patients with drug‐induced immune hemolytic anemia (CME)
BACKGROUND: Ceftriaxone, a third‐generation cephalosporin, is commonly used to prevent and treat infections. Since 1987, it has been the second most common cause of drug‐induced immune hemolytic anemia (DIIHA) investigated in our laboratory.STUDY DESIGN AND METHODS: Samples from 79 patients (1987‐2010), suspected of having DIIHA caused by ceftriaxone, were studied for the presence of ceftriaxone antibodies. Direct antiglobulin tests (DATs) and tests with ceftriaxone‐treated red blood cells (RBCs) or untreated and enzyme‐treated RBCs in the presence of ceftriaxone were performed.RESULTS: Twenty‐five (32%) of the 79 patients had antibodies to ceftriaxone detected. Seventeen (68%) of the 25 patients were children; reactions in children were usually dramatic and severe. Nine (36%) of the 25 patients had fatal DIIHA. Nineteen of the 25 samples had DATs performed by our laboratory; 100% of samples were reactive with anti‐C3 and 47% were reactive with anti‐IgG. All 25 sera had ceftriaxone antibodies detected when testing untreated or ficin‐treated RBCs in the presence of ceftriaxone (resulting in agglutination, hemolysis or sensitization of test RBCs). These antibodies were primarily IgM and reactivity was enhanced by testing ficin‐treated RBCs. Sixteen (64%) of the 25 sera reacted with test RBCs when no ceftriaxone was added in vitro; this was most likely due to the transient presence of drug or drug‐immune complexes in the patient's circulation at the time that the blood samples were drawn.CONCLUSION: Ceftriaxone antibodies can cause severe intravascular hemolysis. Complement can usually be detected on the patient's RBCs and IgM antibodies are usually detected in the patient's serum.
- 31 August 2011
- Published by Wiley in Transfusion
- Vol. 52 (3) , 602-612
Serologic characteristics of ceftriaxone antibodies in 25 patients with drug‐induced immune hemolytic anemia (CME)
BACKGROUND: Ceftriaxone, a third‐generation cephalosporin, is commonly used to prevent and treat infections. Since 1987, it has been the second most common cause of drug‐induced immune hemolytic anemia (DIIHA) investigated in our laboratory.STUDY DESIGN AND METHODS: Samples from 79 patients (1987‐2010), suspected of having DIIHA caused by ceftriaxone, were studied for the presence of ceftriaxone antibodies. Direct antiglobulin tests (DATs) and tests with ceftriaxone‐treated red blood cells (RBCs) or untreated and enzyme‐treated RBCs in the presence of ceftriaxone were performed.RESULTS: Twenty‐five (32%) of the 79 patients had antibodies to ceftriaxone detected. Seventeen (68%) of the 25 patients were children; reactions in children were usually dramatic and severe. Nine (36%) of the 25 patients had fatal DIIHA. Nineteen of the 25 samples had DATs performed by our laboratory; 100% of samples were reactive with anti‐C3 and 47% were reactive with anti‐IgG. All 25 sera had ceftriaxone antibodies detected when testing untreated or ficin‐treated RBCs in the presence of ceftriaxone (resulting in agglutination, hemolysis or sensitization of test RBCs). These antibodies were primarily IgM and reactivity was enhanced by testing ficin‐treated RBCs. Sixteen (64%) of the 25 sera reacted with test RBCs when no ceftriaxone was added in vitro; this was most likely due to the transient presence of drug or drug‐immune complexes in the patient's circulation at the time that the blood samples were drawn.CONCLUSION: Ceftriaxone antibodies can cause severe intravascular hemolysis. Complement can usually be detected on the patient's RBCs and IgM antibodies are usually detected in the patient's serum.
- 22 December 2010
- Published by Wiley in Transfusion Medicine
- Vol. 21 (3) , 194-198
Haemolytic anaemia and renal failure associated with antibodies to trimethoprim and sulfamethoxazole
Aim: The aim of this study was to support a clinical diagnosis of drug‐induced immune haemolytic anaemia (DIIHA). Background: DIIHA is rare and has only been described twice with the antibiotic combination of trimethoprim (TMP) and sulfamethoxazole (SMX). Methods/Materials: Serologic tests for drug antibodies were performed using methods previously published by our laboratory. Results: A 44‐year‐old woman experienced body aches, chills, chest pressure, nausea and a rash while receiving TMP–SMX; a week later her haemoglobin was low and she was in renal failure. At the hospital, the direct antiglobulin test (DAT) was positive (C3 only) and the serum reacted with all red blood cells (RBCs) by the gel method only (TMP–SMX is present in the RBC diluent used for the gel method). At the Red Cross immunohaematology laboratory, the patient's serum was reactive in the presence of TMP–SMX (haemolysis and positive antiglobulin test), pure TMP (positive antiglobulin test using anti‐IgG only) and pure SMX (haemolysis and positive antiglobulin test using both anti‐IgG and anti‐C3). The patient was treated with transfusions and haemodialysis and was discharged after a week in stable condition. Conclusion: We describe a patient who appeared to have haemolytic anaemia and renal failure associated with antibodies to both TMP and SMX.
- 22 December 2010
- Published by Wiley in Transfusion Medicine
- Vol. 21 (3) , 194-198
Haemolytic anaemia and renal failure associated with antibodies to trimethoprim and sulfamethoxazole
Aim: The aim of this study was to support a clinical diagnosis of drug‐induced immune haemolytic anaemia (DIIHA). Background: DIIHA is rare and has only been described twice with the antibiotic combination of trimethoprim (TMP) and sulfamethoxazole (SMX). Methods/Materials: Serologic tests for drug antibodies were performed using methods previously published by our laboratory. Results: A 44‐year‐old woman experienced body aches, chills, chest pressure, nausea and a rash while receiving TMP–SMX; a week later her haemoglobin was low and she was in renal failure. At the hospital, the direct antiglobulin test (DAT) was positive (C3 only) and the serum reacted with all red blood cells (RBCs) by the gel method only (TMP–SMX is present in the RBC diluent used for the gel method). At the Red Cross immunohaematology laboratory, the patient's serum was reactive in the presence of TMP–SMX (haemolysis and positive antiglobulin test), pure TMP (positive antiglobulin test using anti‐IgG only) and pure SMX (haemolysis and positive antiglobulin test using both anti‐IgG and anti‐C3). The patient was treated with transfusions and haemodialysis and was discharged after a week in stable condition. Conclusion: We describe a patient who appeared to have haemolytic anaemia and renal failure associated with antibodies to both TMP and SMX.
- 1 February 2010
- Published by Wiley in Transfusion
- Vol. 50 (2) , 302-307
Immune hemolytic anemia due to cimetidine: the first example of a cimetidine antibody
BACKGROUND: Although there have been a few reports of immune hemolytic anemia (IHA) thought to be due to cimetidine, none of them provided proof (e.g., serologic detection of anti‐cimetidine and/or repeat of IHA upon drug rechallenge). One report used cimetidine as an example of how temporal associations of drug administration and hemolytic anemia are not proof of a cause‐effect relationship.STUDY DESIGN AND METHODS: A 63‐year‐old cancer patient developed IHA on two occasions after receiving cimetidine (with and without chemotherapy). Serologic methods included testing cimetidine‐treated red blood cells (RBCs) as well as testing untreated RBCs in the presence of cimetidine.RESULTS: The patient's direct antiglobulin test was positive (C3 only) and a serum antibody to cimetidine was detected by both testing methods. An eluate from the patient's RBCs was nonreactive. Cimetidine‐treated RBCs were optimally prepared at room temperature and needed to be tested on the day of preparation.CONCLUSIONS: This is the first reported case of IHA due to a cimetidine antibody where a drug‐dependent antibody was demonstrated. The patient had IHA after receiving cimetidine on two separate occasions.
- 1 February 2010
- Published by Wiley in Transfusion
- Vol. 50 (2) , 302-307
Immune hemolytic anemia due to cimetidine: the first example of a cimetidine antibody
BACKGROUND: Although there have been a few reports of immune hemolytic anemia (IHA) thought to be due to cimetidine, none of them provided proof (e.g., serologic detection of anti‐cimetidine and/or repeat of IHA upon drug rechallenge). One report used cimetidine as an example of how temporal associations of drug administration and hemolytic anemia are not proof of a cause‐effect relationship.STUDY DESIGN AND METHODS: A 63‐year‐old cancer patient developed IHA on two occasions after receiving cimetidine (with and without chemotherapy). Serologic methods included testing cimetidine‐treated red blood cells (RBCs) as well as testing untreated RBCs in the presence of cimetidine.RESULTS: The patient's direct antiglobulin test was positive (C3 only) and a serum antibody to cimetidine was detected by both testing methods. An eluate from the patient's RBCs was nonreactive. Cimetidine‐treated RBCs were optimally prepared at room temperature and needed to be tested on the day of preparation.CONCLUSIONS: This is the first reported case of IHA due to a cimetidine antibody where a drug‐dependent antibody was demonstrated. The patient had IHA after receiving cimetidine on two separate occasions.
- 20 March 2009
- Published by Wiley in Transfusion
- Vol. 49 (4) , 711-718
Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug‐induced nonimmunologic protein adsorption
BACKGROUND: Two patients were suspected of having immune hemolytic anemia (IHA) due to oxaliplatin. A related drug, cisplatin, is known to cause nonimmunologic protein adsorption (NIPA). Studies were performed to determine the presence of oxaliplatin‐dependent antibodies in addition to oxaliplatin‐induced NIPA.STUDY DESIGN AND METHODS: Sera and eluates from the two patients were tested against red blood cells (RBCs) treated with oxaliplatin, cisplatin, and carboplatin (another platinum drug). Sera were also tested against untreated RBCs in the presence of the same drugs. Testing with pooled normal sera and anti‐human albumin was used to demonstrate the presence of NIPA. Oxaliplatin‐treated RBCs sensitized with the patients' sera and pooled normal sera were tested by a monocyte monolayer assay (MMA) to determine potential clinical significance.RESULTS: Both patients had high‐titer antibodies to oxaliplatin in their sera that reacted with oxaliplatin‐treated RBCs and with untreated RBCs in the presence of oxaliplatin. RBCs treated with oxaliplatin, cisplatin, and carboplatin all demonstrated NIPA (pooled normal sera and anti‐human albumin were reactive to low titers). NIPA was also detected in tests with untreated RBCs in the presence of oxaliplatin and cisplatin. Lower‐titer reactivity of both patients' sera with cisplatin may have been due to NIPA and/or cross‐reactivity of anti‐oxaliplatin with cisplatin. MMAs were weakly positive due to NIPA and more strongly positive due to oxaliplatin antibodies.CONCLUSION: Two patients with IHA were demonstrated to have oxaliplatin‐dependent antibodies. Oxaliplatin was also shown to cause NIPA. The drug‐dependent antibody and/or the drug‐induced NIPA could have contributed to the patients' hemolytic anemia.
- 20 March 2009
- Published by Wiley in Transfusion
- Vol. 49 (4) , 711-718
Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug‐induced nonimmunologic protein adsorption
BACKGROUND: Two patients were suspected of having immune hemolytic anemia (IHA) due to oxaliplatin. A related drug, cisplatin, is known to cause nonimmunologic protein adsorption (NIPA). Studies were performed to determine the presence of oxaliplatin‐dependent antibodies in addition to oxaliplatin‐induced NIPA.STUDY DESIGN AND METHODS: Sera and eluates from the two patients were tested against red blood cells (RBCs) treated with oxaliplatin, cisplatin, and carboplatin (another platinum drug). Sera were also tested against untreated RBCs in the presence of the same drugs. Testing with pooled normal sera and anti‐human albumin was used to demonstrate the presence of NIPA. Oxaliplatin‐treated RBCs sensitized with the patients' sera and pooled normal sera were tested by a monocyte monolayer assay (MMA) to determine potential clinical significance.RESULTS: Both patients had high‐titer antibodies to oxaliplatin in their sera that reacted with oxaliplatin‐treated RBCs and with untreated RBCs in the presence of oxaliplatin. RBCs treated with oxaliplatin, cisplatin, and carboplatin all demonstrated NIPA (pooled normal sera and anti‐human albumin were reactive to low titers). NIPA was also detected in tests with untreated RBCs in the presence of oxaliplatin and cisplatin. Lower‐titer reactivity of both patients' sera with cisplatin may have been due to NIPA and/or cross‐reactivity of anti‐oxaliplatin with cisplatin. MMAs were weakly positive due to NIPA and more strongly positive due to oxaliplatin antibodies.CONCLUSION: Two patients with IHA were demonstrated to have oxaliplatin‐dependent antibodies. Oxaliplatin was also shown to cause NIPA. The drug‐dependent antibody and/or the drug‐induced NIPA could have contributed to the patients' hemolytic anemia.
- 23 January 2009
- Published by Wiley in Transfusion
- Vol. 49 (2) , 235-242
Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies
BACKGROUND: Autoimmune hemolytic anemia (AIHA) associated with immunoglobulin M (IgM) warm autoantibodies is unusual but often severe, with more fatalities than other types of AIHA. Diagnosing this type of AIHA can be difficult because routine serologic data are not always informative.STUDY DESIGN AND METHODS: Forty‐nine cases of IgM warm AIHA in 25 years were studied by serologic methods.RESULTS: Routine direct antiglobulin tests (DATs) detected red blood cell (RBC)‐bound C3 in 90 percent of cases (65% had C3 but no immunoglobulin G [IgG] on their RBCs) and IgG in 24 percent. IgM was detected on 29 of 47 (62%) patients' RBCs; RBC‐bound IgM was detected in 14 of 47 cases by a tube DAT method and in an additional 15 of 21 (71%) cases using fluorescein isothiocyanate anti‐IgM and flow cytometry. Eighty‐one percent of eluates from patients' RBCs reacted. Warm autoagglutinins were present in 94 percent of serum samples; untreated and enzyme‐treated RBCs were hemolyzed at 37°C by 13 and 65 percent of serum samples, respectively. Most agglutinins were optimally reactive at 30 to 37°C. Patients' RBCs were spontaneously agglutinated in 78 percent of cases; washing with 37°C saline or treating RBCs with dithiothreitol resolved this problem. Clear specificity of autoantibody was defined in 35 percent of serum samples.CONCLUSION: IgM warm AIHA can be confused with cold agglutinin syndrome and “mixed/combined”‐type AIHA; a serologic workup by a specialist reference laboratory can help with the diagnosis.
- 23 January 2009
- Published by Wiley in Transfusion
- Vol. 49 (2) , 235-242
Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies
BACKGROUND: Autoimmune hemolytic anemia (AIHA) associated with immunoglobulin M (IgM) warm autoantibodies is unusual but often severe, with more fatalities than other types of AIHA. Diagnosing this type of AIHA can be difficult because routine serologic data are not always informative.STUDY DESIGN AND METHODS: Forty‐nine cases of IgM warm AIHA in 25 years were studied by serologic methods.RESULTS: Routine direct antiglobulin tests (DATs) detected red blood cell (RBC)‐bound C3 in 90 percent of cases (65% had C3 but no immunoglobulin G [IgG] on their RBCs) and IgG in 24 percent. IgM was detected on 29 of 47 (62%) patients' RBCs; RBC‐bound IgM was detected in 14 of 47 cases by a tube DAT method and in an additional 15 of 21 (71%) cases using fluorescein isothiocyanate anti‐IgM and flow cytometry. Eighty‐one percent of eluates from patients' RBCs reacted. Warm autoagglutinins were present in 94 percent of serum samples; untreated and enzyme‐treated RBCs were hemolyzed at 37°C by 13 and 65 percent of serum samples, respectively. Most agglutinins were optimally reactive at 30 to 37°C. Patients' RBCs were spontaneously agglutinated in 78 percent of cases; washing with 37°C saline or treating RBCs with dithiothreitol resolved this problem. Clear specificity of autoantibody was defined in 35 percent of serum samples.CONCLUSION: IgM warm AIHA can be confused with cold agglutinin syndrome and “mixed/combined”‐type AIHA; a serologic workup by a specialist reference laboratory can help with the diagnosis.
- Open Access
- 26 March 2008
- Published by Wiley in American Journal of Hematology
- Vol. 83 (8) , 657-667
Blood doping in athletes—Detection of allogeneic blood transfusions by flow cytofluorometry
Athletes may undergo blood transfusion to increase their red cell mass and the oxygen carrying capacity of their blood in order to confer a competitive advantage. Allogeneic transfusions are normally mismatched at one or more minor blood group antigens. The most sensitive and accurate method known to detect this form of blood doping is flow cytometry. Low percentages of antigen‐positive and antigen‐negative red blood cells (RBCs) can be quantitated using suitable specific alloantibodies and careful analysis. By testing blood samples taken at various times, a reduction in the percentage of a minor population of RBCs will indicate transfusion has occurred. Am. J. Hematol., 2008.
- 26 March 2008
- Published by Wiley in American Journal of Hematology
- Vol. 83 (8) , 657-667
Open AccessBlood doping in athletes—Detection of allogeneic blood transfusions by flow cytofluorometry
Athletes may undergo blood transfusion to increase their red cell mass and the oxygen carrying capacity of their blood in order to confer a competitive advantage. Allogeneic transfusions are normally mismatched at one or more minor blood group antigens. The most sensitive and accurate method known to detect this form of blood doping is flow cytometry. Low percentages of antigen‐positive and antigen‐negative red blood cells (RBCs) can be quantitated using suitable specific alloantibodies and careful analysis. By testing blood samples taken at various times, a reduction in the percentage of a minor population of RBCs will indicate transfusion has occurred. Am. J. Hematol., 2008.
- 1 July 2005
- Published by Elsevier in Seminars in Hematology
- Vol. 42 (3) , 137-144
The Changing Spectrum of Drug-Induced Immune Hemolytic Anemia
- 1 July 2005
- Published by Elsevier in Seminars in Hematology
- Vol. 42 (3) , 137-144
The Changing Spectrum of Drug-Induced Immune Hemolytic Anemia
- 27 April 2005
- Published by Wiley in Transfusion Medicine
- Vol. 15 (2) , 125-132
Late onset neonatal anaemia due to maternal anti‐Ge: possible association with destruction of eythroid progenitors
summary. There have been no reports of severe haemolytic disease of the newborn (HDN) due to Gerbich (Ge) antibodies. Two babies with HDN due to anti‐Ge3, both born to the same mother, are described. The anti‐Ge appeared in the first pregnancy and was not detectable in the first trimester, the babies' reticulocyte and bilirubin values were not greatly elevated (similar to HDN due to Kell antibodies), and the anaemia in both cases was either not apparent or not severe until 2 to 4 weeks after birth. Ge antigens are found on glycophorins (GPs) C and D; GPC, like Kell, has been shown to be expressed early on erythroid progenitor cells. The maternal anti‐Ge3 was shown to promote phagocytosis of Ge+ early erythroid progenitors by monocytes (similar to what has been reported with anti‐K and K+ progenitor cells). Thus, anti‐Ge3 may cause immune destruction of erythroid progenitors and possibly suppression of erythropoiesis (which would explain the reticulocyte and bilirubin values seen in both cases). Anti‐Ge3 appears to be capable of causing severe HDN. We suggest that babies born to mothers with anti‐Ge should have their haemoglobin concentrations monitored for signs of anaemia for several weeks after birth. Functional assays may prove useful.
- 27 April 2005
- Published by Wiley in Transfusion Medicine
- Vol. 15 (2) , 125-132
Late onset neonatal anaemia due to maternal anti‐Ge: possible association with destruction of eythroid progenitors
summary. There have been no reports of severe haemolytic disease of the newborn (HDN) due to Gerbich (Ge) antibodies. Two babies with HDN due to anti‐Ge3, both born to the same mother, are described. The anti‐Ge appeared in the first pregnancy and was not detectable in the first trimester, the babies' reticulocyte and bilirubin values were not greatly elevated (similar to HDN due to Kell antibodies), and the anaemia in both cases was either not apparent or not severe until 2 to 4 weeks after birth. Ge antigens are found on glycophorins (GPs) C and D; GPC, like Kell, has been shown to be expressed early on erythroid progenitor cells. The maternal anti‐Ge3 was shown to promote phagocytosis of Ge+ early erythroid progenitors by monocytes (similar to what has been reported with anti‐K and K+ progenitor cells). Thus, anti‐Ge3 may cause immune destruction of erythroid progenitors and possibly suppression of erythropoiesis (which would explain the reticulocyte and bilirubin values seen in both cases). Anti‐Ge3 appears to be capable of causing severe HDN. We suggest that babies born to mothers with anti‐Ge should have their haemoglobin concentrations monitored for signs of anaemia for several weeks after birth. Functional assays may prove useful.
- 17 August 2004
- Published by Wiley in Transfusion
- Vol. 44 (9) , 1273-1281
A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies
BACKGROUND: Cellular assays (e.g., monocyte monolayer assays [MMAs]) have been used to predict the clinical significance of red blood cell (RBC) alloantibodies.STUDY DESIGN AND METHODS: Twenty years of MMA data were retrospectively analyzed to 1) determine the optimal cut point (by correlating MMA results from 46 patients with RBC survival study results and/or laboratory and clinical signs of hemolytic transfusion reactions [HTRs] when incompatible blood was transfused), and 2) determine what percentage of 251 unusual alloantibodies (most to high‐incidence antigens) were predicted to be clinically significant.RESULTS: Two MMA cut points (5% and 20%) were chosen using a receiver‐operating characteristics curve. No patients with MMA results less than or equal to 5 percent had clinical signs of a reaction; one‐third of patients with MMA results 5.1 to 20 percent versus two‐thirds with results greater than 20 percent had clinical signs of a HTR after transfusion of incompatible blood. Using 5‐percent or 20‐percent cut points, 173 (69%) or 97 (39%) of 251 unusual alloantibodies gave positive MMAs, respectively.CONCLUSION: A negative MMA (≤5%) indicates that incompatible blood can be given without risk of an overt HTR but does not guarantee normal long‐term survival of those RBCs. Most unusual alloantibodies are predicted to cause shortened RBC survival, but transfusion of incompatible blood may not result in any clinical or laboratory signs of a HTR. We have used the MMA for approximately 20 years, instead of a 1‐hour chromium‐51 RBC survival, to aid in the decision to transfuse RBCs incompatible with antibodies to high‐incidence antigens.
- 17 August 2004
- Published by Wiley in Transfusion
- Vol. 44 (9) , 1273-1281
A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies
BACKGROUND: Cellular assays (e.g., monocyte monolayer assays [MMAs]) have been used to predict the clinical significance of red blood cell (RBC) alloantibodies.STUDY DESIGN AND METHODS: Twenty years of MMA data were retrospectively analyzed to 1) determine the optimal cut point (by correlating MMA results from 46 patients with RBC survival study results and/or laboratory and clinical signs of hemolytic transfusion reactions [HTRs] when incompatible blood was transfused), and 2) determine what percentage of 251 unusual alloantibodies (most to high‐incidence antigens) were predicted to be clinically significant.RESULTS: Two MMA cut points (5% and 20%) were chosen using a receiver‐operating characteristics curve. No patients with MMA results less than or equal to 5 percent had clinical signs of a reaction; one‐third of patients with MMA results 5.1 to 20 percent versus two‐thirds with results greater than 20 percent had clinical signs of a HTR after transfusion of incompatible blood. Using 5‐percent or 20‐percent cut points, 173 (69%) or 97 (39%) of 251 unusual alloantibodies gave positive MMAs, respectively.CONCLUSION: A negative MMA (≤5%) indicates that incompatible blood can be given without risk of an overt HTR but does not guarantee normal long‐term survival of those RBCs. Most unusual alloantibodies are predicted to cause shortened RBC survival, but transfusion of incompatible blood may not result in any clinical or laboratory signs of a HTR. We have used the MMA for approximately 20 years, instead of a 1‐hour chromium‐51 RBC survival, to aid in the decision to transfuse RBCs incompatible with antibodies to high‐incidence antigens.
- Open Access
- 18 March 2004
- Published by Wiley in British Journal of Haematology
- Vol. 125 (3) , 412-414
Rhnull red blood cells with reduced CD47 do not show increased interactions with peripheral blood monocytes
- 18 March 2004
- Published by Wiley in British Journal of Haematology
- Vol. 125 (3) , 412-414
Open AccessRhnull red blood cells with reduced CD47 do not show increased interactions with peripheral blood monocytes